GU Cancers 2024 | Real-world efficacy of avelumab and axitinib in advanced renal cell carcinoma

Anand Sharma, MD, DPhil, MBBS, MRCP, Mount Vernon Cancer Centre, Northwood, UK, provides an overview of results from a retrospective study that evaluated real-world outcomes in British patients with treatment-naïve advanced renal cell carcinoma (aRCC) receiving first-line avelumab and axitinib. Objective response rate in real-world settings were consistent with clinical trial findings such as the JAVELIN Renal 101 trial (NCT02684006) and no new safety concerns were reported. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.